Distinguished in Allergic Conjunctivitis

Dr. Gail L. Torkildsen

Ophthalmology
138 Haverhill St, Suite 104, 
Andover, MA 
Distinguished in Allergic Conjunctivitis
138 Haverhill St, Suite 104, 
Andover, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gail Torkildsen is an Ophthalmologist in Andover, Massachusetts. Dr. Torkildsen is rated as a Distinguished provider by MediFind in the treatment of Allergic Conjunctivitis. Her top areas of expertise are Giant Papillary Conjunctivitis, Vernal Keratoconjunctivitis, Allergic Conjunctivitis, and Chemosis.

Her clinical research consists of co-authoring 27 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 11 articles and participated in 1 clinical trial in the study of Allergic Conjunctivitis.

Specialties
Ophthalmology
Licenses
Ophthalmology in MA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Tufts
  • HMO

Locations

138 Haverhill St, Suite 104, Andover, MA 01810

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine /Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine /Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
Enrollment Status: Completed
Publish Date: September 05, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease (COMET-1)
A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease (COMET-1)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: AR15512, Vehicle
Study Phase: Phase 2
Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 2b/3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 2b/3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Drug: Lotilaner Ophthalmic Solution
Study Phase: Phase 2/Phase 3
A Single-Center, Randomized, Double Masked, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of iNexin™ Eye Drops Compared to Vehicle in Subjects With Dry Eye Disease
A Single-Center, Randomized, Double Masked, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of iNexin™ Eye Drops Compared to Vehicle in Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: March 04, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution in Subjects With Dry Eye Using the Controlled Adverse Environment (CAE) Model
A Phase 2, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution in Subjects With Dry Eye Using the Controlled Adverse Environment (CAE) Model
Enrollment Status: Completed
Publish Date: August 09, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Single Center, Randomized, Double-Masked and Placebo Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1, 1.0, 5.0%) of SAR 1118 Ophthalmic Solution in a Modified Conjunctival Allergen Challenge (CAC) Model
A Phase 2, Single Center, Randomized, Double-Masked and Placebo Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1, 1.0, 5.0%) of SAR 1118 Ophthalmic Solution in a Modified Conjunctival Allergen Challenge (CAC) Model
Enrollment Status: Completed
Publish Date: June 11, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
View 5 Less Clinical Trials

27 Total Publications

Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
Published: September 07, 2023
Similar Doctors
Elite in Allergic Conjunctivitis
Dr. Mark B. Abelson
Ophthalmology
Elite in Allergic Conjunctivitis
Dr. Mark B. Abelson
Ophthalmology
138 Haverhill St, Ste 104, 
Andover, MA 
 (0.1 miles away)
978-475-0705
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Abelson is an Ophthalmologist in Andover, Massachusetts. Dr. Abelson is rated as a Distinguished provider by MediFind in the treatment of Allergic Conjunctivitis. His top areas of expertise are Giant Papillary Conjunctivitis, Vernal Keratoconjunctivitis, Allergic Conjunctivitis, and Conjunctivitis (Pink Eye). Dr. Abelson is currently accepting new patients.

Distinguished in Allergic Conjunctivitis
Dr. Joseph B. Ciolino
Ophthalmology
Distinguished in Allergic Conjunctivitis
Dr. Joseph B. Ciolino
Ophthalmology

Massachusetts Eye And Ear Associates, Inc

243 Charles St, 
Boston, MA 
 (21.9 miles away)
617-523-7900
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Joseph Ciolino is an Ophthalmologist in Boston, Massachusetts. Dr. Ciolino is rated as a Distinguished provider by MediFind in the treatment of Allergic Conjunctivitis. His top areas of expertise are Interstitial Keratitis, Keratoconus, Giant Papillary Conjunctivitis, Vernal Keratoconjunctivitis, and Corneal Transplant. Dr. Ciolino is currently accepting new patients.

Advanced in Allergic Conjunctivitis
Dr. John G. Capino
Ophthalmology
Advanced in Allergic Conjunctivitis
Dr. John G. Capino
Ophthalmology
1230 Bridge St, Suite 2, 
Lowell, MA 
 (8.6 miles away)
978-452-2100
Languages Spoken:
English, Filipino, Spanish
See accepted insurances
Accepting New Patients

John Capino is an Ophthalmologist in Lowell, Massachusetts. Dr. Capino is rated as an Advanced provider by MediFind in the treatment of Allergic Conjunctivitis. His top areas of expertise are Conjunctivitis (Pink Eye), Allergic Conjunctivitis, Cataract, and Pterygium. Dr. Capino is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Torkildsen's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile